3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
3
Genitourinary
2
Gastrointestinal
2
Thoracic
1
Gynecologic
1
Dermatologic
1
Breast
1
Conditions
Lung Neoplasms
5
Small Cell Lung Carcinoma
4
Mesothelioma
3
Neoplasms
2
Neoplasm Metastasis
2
Mesothelioma, Malignant
2
Carcinoma, Non-Small-Cell Lung
2
Uveal Melanoma
1
Urologic Neoplasms
1
Stomach Neoplasms
1
SCLC,Extensive Stage
1
Recurrence
1
Pancreatic Neoplasms
1
Melanoma
1
Head and Neck Neoplasms
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Colonic Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Squamous Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Neuroendocrine
1
Carcinoma
1
Breast Neoplasms
1
Anus Neoplasms
1
Interventions
pembrolizumab
34
Cisplatin
12
Nivolumab
10
atezolizumab
9
Docetaxel
9
Carboplatin
9
Paclitaxel
8
Cetuximab
8
Gemcitabine
7
Blood Specimen Collection
7
Radiotherapy
6
Fluorouracil
6
Drug Therapy
6
cemiplimab
5
Pemetrexed
5
Immune Checkpoint Inhibitors
5
fludarabine
4
Standard of Care
4
Cyclophosphamide
4
spartalizumab
3
epacadostat
3
Surveys and Questionnaires
3
Oncolytic Virotherapy
3
Nicotine
3
Magnetic Resonance Spectroscopy
3
Irinotecan
3
Interleukin-2
3
Filgrastim
3
Bupropion
3
Bortezomib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Head and Neck Neoplasms
×
niraparib
×
Thoracic
×
Clear all
NCT05169437
2025-10-29
PAVO
Tempus AI
Phase 2
Terminated
22 enrolled
17 charts